Robinhood, Applovin jump as S&P 500 reshuffle boosts index entrants
Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $11.7 billion market cap biopharmaceutical company, recently sold 700 shares of the company’s common stock, according to a recent SEC filing. The timing is notable as the stock has declined 22% in the past week and is trading near its 52-week low. The shares were sold at a weighted average price of $118.275, amounting to a total transaction value of $82,792. This sale was executed as part of a pre-arranged trading plan under Rule 10b5-1.
Prior to this sale, Cooke acquired 1,329 shares through the vesting of restricted stock units on February 8, 2025. These shares were acquired at no cost as part of her compensation package. Following these transactions, Cooke holds 18,831 shares directly, with an additional 16,538 shares held by the Cooke Family Trust of 2004, over which she has voting and investment power.
In other recent news, Neurocrine Biosciences has been in the spotlight with several financial firms adjusting their stock targets. Deutsche Bank (ETR:DBKGn) initiated coverage with a Hold rating and set a price target of $138. The bank’s analysis suggests that significant appreciation in Neurocrine’s stock price may require investor confidence in an asset comparable to its Ingrezza treatment.
UBS, on the other hand, reduced the price target to $154 from $176 while maintaining a Buy rating. The revised target reflects a more conservative growth trajectory for Ingrezza, Neurocrine’s lead product. Similarly, Guggenheim maintained a Buy rating but lowered the price target to $163 due to Ingrezza sales falling slightly below consensus estimates.
H.C. Wainwright also adjusted the price target to $185 from the previous $190, maintaining a Buy rating on the stock. This revision followed the company’s announcement that Ingrezza generated revenue of $615 million, slightly missing consensus forecasts.
These are recent developments in the financial analysis of Neurocrine Biosciences. While these adjustments in stock targets reflect the company’s recent earnings and revenue results, they also illustrate the ongoing interest and scrutiny from financial institutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.